Efficacy and Safety for Medicurtain® in Prevention of Adhesion After Endoscopic Sinus Surgery (Pivotal Study)

NCT ID: NCT05049434

Last Updated: 2021-09-20

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 77 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2014-03-03
• Study Completion Date: 2015-03-31

Brief Summary

This clinical trial is to prove that the treatment group of Medicurtain® is non-inferior to the treatment group of Guardix-sol®, test equipment on adhesion after endoscopic sinus surgery, upon the aspects of adhesion prevention efficacy and safety.

Detailed Description

This clinical trial was conducted based on multi center, randomized, assessor blind, matched pair design, active-controlled clinical study. After signing consent and fulfilling the standards for selection/exclusion, test subjects went through required treatments following endoscopic surgery; subsequently, according to the order of registration after 2 to 3 days from the surgery, the subjects were applied with a medical device for the clinical test and a medical device for the control test to both of their nasal cavities based on randomization.

For procedures, bleeding was treated and prevented through packing, by soaking Merocel with saline solution following the ESS (Endoscopic sinus surgery) on subjects; and after 2 to 3 days (or upon discharge), it was to treat applied regions of the subjects with assigned medical device after confirming sufficient hemostasis by removing Merocel. Being matched pair active-controlled clinical study, this clinical trial was designed to treat a single subject with both medical devices for clinical test and control test where it was kept unknown which device would be assigned to which nasal cavity based on randomization until the procedure was actually performed. For the time and method of evaluation, observation and evaluation were allowed to be conducted based on the images through endoscopy when subjects visited at 1st, 2nd and 4th weeks following the treatment with medical device. The process of procedure was assured for an identical researcher to perform procedures in order to minimize the effect from the procedure method.

All endoscopic image records of test subjects were delivered by independent assessors, while information on medical device used for treatment was excluded; and independent assessors evaluated each image record according to the evaluation standards prescribed by this clinical trial.

Based on the determination of the researcher during and following the surgery, subjects were administered with 2nd or 3rd generation Cephalosporin Antibiotics. Following the surgery, subjects were instructed to use normal saline solution nasal spray 2 to 3 times a day on both nasal cavities by utilizing bulb-shape tube or syringe. In addition, subjects were also instructed to use intranasal steroid sprays.

Conditions

Sinusitis; Tissue Adhesion, Surgery-Induced

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: PREVENTION
• Blinding Strategy: DOUBLE

Study Groups

Medicurtain®

Treat GUARDIX-SG 5ml prefilled syringe after surgery

Group Type: EXPERIMENTAL

Medicurtain®

Intervention Type: DEVICE

Medicurtain® 5ml prefilled syringe

GUARDIX-SG®

Treat Medicurtain® 5ml prefilled syringe after surgery

Group Type: ACTIVE_COMPARATOR

GUARDIX-SG®

Intervention Type: DEVICE

GUARDIX-SG® 5ml prefilled syringe

Interventions

Medicurtain®

Medicurtain® 5ml prefilled syringe

Intervention Type: DEVICE

GUARDIX-SG®

GUARDIX-SG® 5ml prefilled syringe

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

1. Patients at the age of between 19 and 69

2. Patients scheduled for surgery with chronic or relapsed sinusitis not responding to drug therapy (Verification to be made based on past clinical history, physical examination and radiography)

3. Patients with the discrepancy of Lund-MacKay CT scan scores on bilateral sinusitis less than 3

4. Patients who signed written consent after listening to the objective, method and effects of clinical trial

5. Patients available during the period of clinical trial

Exclusion Criteria

1. Patients with sinusitis on only one nasal cavity

2. Patients with massive sinonasal polyposis

3. Patients with one or both middle turbinate removed, in addition to a history of endoscopic surgery or polyp operation

4. Patients with ongoing drug administration for asthma

5. Patients with immune disorders which may potentially hinder healing of the wounds including acquired immunodeficiency syndrome, cystofibroma, immotile cilia syndrome, neutropenia and immune globulin deficiency

6. Patients with immunosuppression or autoimmune disease

7. Patients with hypersensitivity reaction to Poloxamer and Hyaluronic acid

8. Patients who had surgery to treat extrasinus complication from rhinosinusitis

9. Patients with history of endoscopic sinus surgery for other than chronic or relapsed sinusitis, including cerebrospinal fluid (CSF) leak correction, orbital decompression and optic nerve decompression

10. Patients with significant liver or kidney diseases

11. Patients with setting agent administered or with hemostatic or lymph fluid disorders

12. Patients administered with oral or parenteral drugs for hypoglycemia

13. Patients with significant systematic disease

14. Patients with malignant tumor

15. Patients with infectious disease or suspected of potential problems during the course of healing surgical site (healing disorder)

16. Those who are pregnant or lactiferous

17. Women of childbearing age with plan for pregnancy during the clinical trial period

18. Those who participated in other clinical trials 30 days prior to the participation in this trial

19. In addition to the above, those who are subject to clinical findings where principal investigator or sub-investigator deem inadequate for this clinical trial based on medical judgment

• Minimum Eligible Age: 19 Years
• Maximum Eligible Age: 69 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Shin Poong Pharmaceutical Co. Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Heung-Man Lee, MD

Role: PRINCIPAL_INVESTIGATOR

Korea University, Guro Hospital 148 Gurodong-ro, Guro-gu, Seoul

Kyung-su Kim, MD

Role: PRINCIPAL_INVESTIGATOR

Gangnam Severance Hospital Yonsei University, 146-92 Dogok-dong, Gangnam-gu, Seoul

Locations

Korea University Guro Hospital

Seoul, , South Korea

Countries

South Korea

Other Identifiers

UMT2012-SP-MC-04

Identifier Type: -

Identifier Source: org_study_id